As drugs originally developed for people with type 2 diabetes become increasingly popular for their weight loss effects, ramifications are being felt in a number of ways.
Novo Nordisk (NVO) , for example, manufactures Ozempic and Wegovy. Ozempic is approved by the Food and Drug Administration (FDA) for treating diabetes, and Wegovy is approved by the FDA for weight management.
These drugs, known as GLP-1 medications, have recently been the subject of some controversy as supply shortages for people with diabetes have been caused because of demand by others for the medications’ weight-loss effects.
But the increased use of the drugs for weight loss also affects the fitness industry.
The Street recently caught up with Sabrena Jo, senior director of science and research at the American Council on Exercise (ACE), a nonprofit organization that certifies health coaches and exercise professionals.
“The ACE mission inspires us to collaborate with like-minded organizations, top research institutions, policymakers on the federal and state level, fitness industry leaders and diverse community organizations to increase physical activity for improved public health,” writes the ACE website.
TheStreet exchanged some questions and answers with Jo and gathered some of her thoughts about the weight loss drugs and their impact on the fitness industry and its clients.
As drugs originally developed for people with type 2 diabetes become increasingly popular for their weight loss effects, ramifications are being felt in a number of ways.
Novo Nordisk (NVO) , for example, manufactures Ozempic and Wegovy. Ozempic is approved by the Food and Drug Administration (FDA) for treating diabetes, and Wegovy is approved by the FDA for weight management.
These drugs, known as GLP-1 medications, have recently been the subject of some controversy as supply shortages for people with diabetes have been caused because of demand by others for the medications’ weight-loss effects.
But the increased use of the drugs for weight loss also affects the fitness industry.
The Street recently caught up with Sabrena Jo, senior director of science and research at the American Council on Exercise (ACE), a nonprofit organization that certifies health coaches and exercise professionals.
“The ACE mission inspires us to collaborate with like-minded organizations, top research institutions, policymakers on the federal and state level, fitness industry leaders and diverse community organizations to increase physical activity for improved public health,” writes the ACE website.
TheStreet exchanged some questions and answers with Jo and gathered some of her thoughts about the weight loss drugs and their impact on the fitness industry and its clients.